Though its use hinges on weight-focused outcomes rather than glucose, individuals managing both weight and metabolic health see dual benefits
Tirzepatide is a single novel molecule that activates the bodys receptors for GIP and GLP-1, which are natural incretin hormones
Highlights from the July 2024 study include: Our main finding is that prescribed semaglutide is associated with an increased risk of NAION. Patients with diabetes who took semaglutide were more than four times more likely to develop NAION than those on other medications
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Published January 6, 2025 Over the past few years, the use of glucagon-like peptide-1 (GLP-1) receptor agonist medicines to help people manage their weight and/or diabetes has exploded
Body weight was notably lower in PIONEER 9 and 10, which ranged from 68.0 kg to 74.7 kg, compared to the other PIONEER trials where the mean body weight was between 84.6 kg and 95.5 kg